Glaucoma is a leading cause of irreversible blindness worldwide, and currently available treatments only offer temporary relief of symptoms. Studies have found the main risk factor for glaucoma is high IOP, primarily due to RGC injury and death. For this reason, Ace Therapeutics offers glaucoma gene therapy development services, targeting IOP and RGC-associated candidate genes, as well as many...

Drug metabolism and pharmacokinetics (DMPK) play a crucial role in the drug development process for stroke. DMPK studies involve the evaluation of how drugs are metabolized and distributed in the body, as well as how they are eliminated from the body. These studies provide important information about the safety and efficacy of a drug and help researchers determine the optimal dosing regimen for...

Ace Therapeutics, a leading provider of preclinical research services and products, is proud to announce the launch of its extensive suite of diabetic mouse models. These models have been specifically designed to enable research on different types of diabetes including type 1, type 2, and gestational diabetes, providing valuable insights into disease mechanisms and potential treatment options....

Ace Therapeutics, a preclinical contract research organization (CRO) actively engaged in mental illness research, has announced the launch of its model development services, which aim to revolutionize psychiatric drug research and development.   Psychiatric drug development is a crucial aspect of mental health treatment, as it involves the development of medications that can effectively...